Observational studyMedicine2025
Determinants of virological failure among people living with HIV receiving first-line antiretroviral therapy in Hiwot Fana Comprehensive University Hospital, Eastern Ethiopia.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Viral suppression status and associated factors among key populations on ART in Western Oromia, Ethiopia: a retrospective analysis.AIDS research and therapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monitoring viral load among patients receiving antiretroviral therapy (ART) is essential to detecting treatment failures, drug resistance, and inappropriate changes to second-line treatment regimens. Determinants of virological failure (VF) among human immunodeficiency virus patients has been scarcely studied in the current study area. Therefore this study aimed to determine the factors that contribute to determinants of virological failure among people living with human immunodeficiency virus receiving first-line ART in Hiwot Fana Comprehensive University Hospital, Eastern Ethiopia. A case-control study was conducted from November 28 to December 11, 2022. We recruited all 246 eligible cases (patients with a viral load of >1000 copies/mL) and randomly selected 246 control patients (viral load ≤1000 copies/mL). Data were extracted from the patient's medical records, including their ART intake, registration, and follow-up details. We employed binary logistic regression to fit both bivariable and multivariable models, and then statistical significance was declared at a P-value of ≤.05. This study showed that age under 35 years (AOR = 1.99, 95%CI: 1.22, 3.25), CD4 count of <200 cells/mm3 (AOR = 6.46, 95% CI: 3.19, 13.09) or 200-499 cells/mm3 (AOR = 2.44, 95% CI: 1.37, 4.35), World Health Organization clinical stage II (AOR = 6.57, 95% CI: 3.72, 11.62) or III (AOR = 4.54, 95% CI: 1.41, 14.58), opportunistic infections (AOR = 5.03, 95% CI: 2.02, 12.50), poor adherence to treatment (AOR = 6.38, 95% CI: 2.64, 15.39), and duration on ART for 48 months (AOR = 8.27, 95% CI: 3.03, 21.13) had higher odds of virologic failure compared to their counterparts. Poor adherence to therapy, longer ART duration, younger age, a low baseline CD4 count, clinical stages II or III, and the presence of opportunistic infection had a significant impact on VF. Adherence counseling and careful monitoring of patients are required to ensure sufficient suppression of viral load.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.